Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Net Income (2016 - 2025)

Ocular Therapeutix has reported Net Income over the past 13 years, most recently at -$65.2 million for Q4 2025.

  • Quarterly results put Net Income at -$65.2 million for Q4 2025, down 33.13% from a year ago — trailing twelve months through Dec 2025 was -$263.5 million (down 59.62% YoY), and the annual figure for FY2025 was -$263.5 million, down 59.62%.
  • Net Income for Q4 2025 was -$65.2 million at Ocular Therapeutix, up from -$68.0 million in the prior quarter.
  • Over the last five years, Net Income for OCUL hit a ceiling of -$19.5 million in Q1 2022 and a floor of -$68.0 million in Q3 2025.
  • Median Net Income over the past 5 years was -$22.9 million (2022), compared with a mean of -$34.4 million.
  • Biggest five-year swings in Net Income: rose 10.95% in 2022 and later tumbled 115.51% in 2024.
  • Ocular Therapeutix's Net Income stood at -$19.7 million in 2021, then dropped by 5.38% to -$20.8 million in 2022, then dropped by 9.42% to -$22.7 million in 2023, then tumbled by 115.51% to -$49.0 million in 2024, then crashed by 33.13% to -$65.2 million in 2025.
  • The last three reported values for Net Income were -$65.2 million (Q4 2025), -$68.0 million (Q3 2025), and -$67.2 million (Q2 2025) per Business Quant data.